JP2011521967A5 - - Google Patents

Download PDF

Info

Publication number
JP2011521967A5
JP2011521967A5 JP2011511835A JP2011511835A JP2011521967A5 JP 2011521967 A5 JP2011521967 A5 JP 2011521967A5 JP 2011511835 A JP2011511835 A JP 2011511835A JP 2011511835 A JP2011511835 A JP 2011511835A JP 2011521967 A5 JP2011521967 A5 JP 2011521967A5
Authority
JP
Japan
Prior art keywords
immune
cells
target
immune system
treating
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2011511835A
Other languages
English (en)
Japanese (ja)
Other versions
JP2011521967A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2009/045550 external-priority patent/WO2009146392A1/en
Publication of JP2011521967A publication Critical patent/JP2011521967A/ja
Publication of JP2011521967A5 publication Critical patent/JP2011521967A5/ja
Withdrawn legal-status Critical Current

Links

JP2011511835A 2008-05-29 2009-05-29 初代細胞由来生物製剤の作用機序 Withdrawn JP2011521967A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US5692508P 2008-05-29 2008-05-29
US61/056,925 2008-05-29
PCT/US2009/045550 WO2009146392A1 (en) 2008-05-29 2009-05-29 Mechanism of action of primary cell derived biologic

Publications (2)

Publication Number Publication Date
JP2011521967A JP2011521967A (ja) 2011-07-28
JP2011521967A5 true JP2011521967A5 (enExample) 2012-11-01

Family

ID=41377590

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2011511835A Withdrawn JP2011521967A (ja) 2008-05-29 2009-05-29 初代細胞由来生物製剤の作用機序

Country Status (7)

Country Link
US (1) US20110081313A1 (enExample)
EP (1) EP2296704A4 (enExample)
JP (1) JP2011521967A (enExample)
AU (1) AU2009251277A1 (enExample)
CA (1) CA2762314A1 (enExample)
MX (1) MX2010012985A (enExample)
WO (1) WO2009146392A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2950109C (en) 2000-10-27 2019-02-19 John W. Hadden Vaccine immunotherapy for immune suppressed patients
US20070025958A1 (en) * 2000-10-27 2007-02-01 Hadden John W Vaccine immunotherapy
US20070154399A1 (en) * 2000-10-27 2007-07-05 Hadden John W Immunotherapy for immune suppressed patients
AU2008329741B2 (en) 2007-11-28 2013-09-12 Irx Therapeutics, Inc. Method of increasing immunological effect
CA3017298C (en) 2009-05-15 2021-09-28 Irx Therapeutics, Inc. Compositions comprising primary cell-derived biologics for enhancing immune responses in patients
CN103097543A (zh) 2009-12-08 2013-05-08 伊尔克斯治疗有限公司 逆转朗格汉斯细胞免疫抑制的方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6667175B1 (en) * 1999-06-15 2003-12-23 The Trustees Of Columbia University Generation of antigen specific T suppressor cells for treatment of rejection
US20070031372A1 (en) * 2004-08-05 2007-02-08 Hadden John W Vaccine immunotherapy for immune suppressed patients
CA2950109C (en) * 2000-10-27 2019-02-19 John W. Hadden Vaccine immunotherapy for immune suppressed patients
US20070025958A1 (en) * 2000-10-27 2007-02-01 Hadden John W Vaccine immunotherapy
ES2553133T3 (es) * 2004-06-04 2015-12-04 Cel-Sci Corporation Método de modificación de la proporción de CD4/CD8 y del infiltrado celular mononuclear en un tumor
WO2006047515A2 (en) * 2004-10-25 2006-05-04 Baylor Research Institute Dendritic cells loaded with heat shocked melanoma cell bodies
ITMI20051209A1 (it) 2005-06-27 2006-12-28 Tecnosanimed S R L Metodo per la predisposizione di set procedurali sterili di strumenti chirurgici per il servizio alle sale operatorie e trattamento di sanificazione tracciabile di sanificazione manutenzione confezionamento e sterilizzazione
EP1996013A4 (en) * 2005-09-21 2010-03-10 Dask Technologies Llc METHODS AND COMPOSITIONS FOR FUNCTIONALITY OF ORGANS AND TISSUES
AU2008329741B2 (en) 2007-11-28 2013-09-12 Irx Therapeutics, Inc. Method of increasing immunological effect

Similar Documents

Publication Publication Date Title
HK1205453A1 (en) Methods of diagnosing and treating motor neuron diseases
JP2011521967A5 (enExample)
CL2013003341A1 (es) Un metodo y sistema para autenticar una sesion de un usuario.
JP2012143233A5 (enExample)
JP2011511805A5 (enExample)
JP2011136997A5 (enExample)
JP2007509067A5 (enExample)
JP2013005803A5 (enExample)
JP2013527965A5 (enExample)
JP2012500090A5 (enExample)
MX388743B (es) Conjugados oligonucleótido-péptido.
CL2014001070A1 (es) Compuestos derivados de aminoácidos funcionalizados en el n-terminal, capaces de formar micro- o nanopartículas para encapsular un agente; composición; uso para tratar enfermedades; y método de suministro de un polinucleótido a una célula.
WO2010037395A3 (en) Mhc multimers in cancer vaccines and immune monitoring
HK1200321A1 (en) Bispecific immunobinders directed against tnf and il-17
JP2011522896A5 (enExample)
EA201001771A1 (ru) Лечение релаксином одышки, ассоциированной с острой сердечной недостаточностью
GT201500046A (es) Mètodos para el tratamiento de infecciones de hepatitis b y hepatitis d
DK2510085T3 (da) Vokenstamcelle-afledt konditioneret medium og/eller voksenstamceller til anvendelse i den terapeutiske behandling af en tumorsygdom
BRPI1008517A2 (pt) direcionamento duplo de mir-208 e mir-499 no tratamento de doenças cardíacas.
WO2013136189A3 (en) Methods and materials for treatment of pompe's disease
CL2012001999A1 (es) Material resistente a la formacion de biopelicula que comprende un agente activo compuesto esencialmente de un oxido de cobre insoluble a una concentracion de entre 3 y 10 % de dicho material resistente a la formacion de biopelicula; y metodo de prevencion, disminucion de incidencia formacion biopeliculas.
FR2967674B1 (fr) Derives d'heteroarylsulfonamides, leur preparation et leur application en therapeutique humaine
PL2859092T3 (pl) Szczepionka terapeutyczna do leczenia cukrzycy typu 1 u dzieci, zastosowanie sortera komórek oraz sposób namnażania komórek Treg do wytwarzania szczepionki do leczenia cukrzycy typu 1
CL2013000202A1 (es) Composicion farmaceutica y combinacion compuesta por una forma potenciada activada de un anticuerpo contra la bradiquinina, una forma potenciada activada de una histamina y una forma potenciada activada de un anticuerpo contra la morfina; metodos para tratar las enfermedades o las condiciones asociadas con la enfermedad o condicion respiratoria.
IT1397011B1 (it) Nanoparticella del tipo core-shell idonea per la veicolazione di oligonucleotidi terapeutici in tessuti bersaglio e suo impiego per la preparazione di un medicamento per il trattamento della distrofia muscolare di duchenne.